Medtronic InFuse Sales Flat In Q2; Firm’s Spine Business Still Struggling
This article was originally published in The Gray Sheet
Executive Summary
Medtronic is exploring alternative distribution channels in oral maxillofacial and trauma markets to grow its struggling InFuse bone graft franchise, the firm said during its Nov. 18 fiscal second-quarter earnings call
You may also be interested in...
News In Brief
Illumina rejects Roche’s increased bid. Medtronic settles shareholder suit over Infuse. HeartWare buys WorldHeart for $8 million. More news briefs.
Medtronic Infuse Saga Prompts Questions About FDA Approval Process
Medtronic, responding last week to suggestions in the Spine Journal that financial ties to the company led researchers to hide serious adverse events associated with the firm's Infuse bone graft when writing up their studies for publication, defended itself by pointing out that the data on which FDA based its approval of the product contained no such omissions.
Medtronic Infuse Saga Prompts Questions About FDA Approval Process
Medtronic, responding last week to suggestions in the Spine Journal that financial ties to the company led researchers to hide serious adverse events associated with the firm's Infuse bone graft when writing up their studies for publication, defended itself by pointing out that the data on which FDA based its approval of the product contained no such omissions.